Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Gary Remington, Ofer Agid & George Foussias. (2011) Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment. Expert Review of Neurotherapeutics 11:4, pages 589-607.
Read now
Read now
Robin Emsley. (2009) Drugs in development for the treatment of schizophrenia. Expert Opinion on Investigational Drugs 18:8, pages 1103-1118.
Read now
Read now
Colin N. Haile, Therese A. Kosten & Thomas R. Kosten. (2008) Pharmacogenetic Treatments for Drug Addiction: Alcohol and Opiates. The American Journal of Drug and Alcohol Abuse 34:4, pages 355-381.
Read now
Read now
Articles from other publishers (31)
Tiffany A. Greenwood. 2023. Cognitive Functioning in Schizophrenia: Leveraging the RDoC Framework. Cognitive Functioning in Schizophrenia: Leveraging the RDoC Framework
291
314
.
Naiara Coelho Ximenes, Manuel Alves Dos Santos Júnior, Germana Silva Vasconcelos, Kátia Cilene Ferreira Dias, Mércia Marques Jucá, Aline Holanda Silva, Luzia Kalyne Almeida Moreira Leal, Glauce Socorro Barros Viana, Francisca Cléa Florenço de Sousa & Silvânia Maria Mendes Vasconcelos. (2019)
Ethanolic extract of
Erythrina velutina
Willd ameliorate schizophrenia-like behavior induced by ketamine in mice
. Journal of Complementary and Integrative Medicine 16:2.
Crossref
Crossref
Katia Cilene Ferreira Dias, Jamily Cunha de Almeida, Luna Costa Vasconcelos, Marianna Letícia Vasconcelos Patrocínio, Talita Matias Barbosa, Naiara Coelho Ximenes, Ana Paula de Azevedo Leitão, Bianca Oliveira Louchard, Antônia Torres Ávila Pimenta, Francisco das Chagas Lima Pinto, Luzia Kalyne Almeida Moreira Leal, José Eduardo Ribeiro Honório Junior & Silvânia Maria Mendes Vasconcelos. (2019) Standardized extract of Erythrina velutina Willd. attenuates schizophrenia-Like behaviours and oxidative parameters in experimental animal models. Journal of Pharmacy and Pharmacology 71:3, pages 379-389.
Crossref
Crossref
Inga Meyhöfer, Veena Kumari, Antje Hill, Nadine Petrovsky & Ulrich Ettinger. (2016) Sleep deprivation as an experimental model system for psychosis: Effects on smooth pursuit, prosaccades, and antisaccades. Journal of Psychopharmacology 31:4, pages 418-433.
Crossref
Crossref
Tatiane da Silva Araújo, Adriano Jose Maia Chaves Filho, Aline Santos Monte, Ana Isabelle de Góis Queiroz, Rafaela Carneiro Cordeiro, Michel de Jesus Souza Machado, Ricardo de Freitas Lima, David Freitas de Lucena, Michael Maes & Danielle Macêdo. (2017) Reversal of schizophrenia-like symptoms and immune alterations in mice by immunomodulatory drugs. Journal of Psychiatric Research 84, pages 49-58.
Crossref
Crossref
Randal G. Ross & Robert Freedman. (2015) Endophenotypes in Schizophrenia for the Perinatal Period: Criteria for Validation. Schizophrenia Bulletin 41:4, pages 824-834.
Crossref
Crossref
Germana Silva Vasconcelos, Naiara Coelho Ximenes, Caren Nádia Soares de Sousa, Tatiana de Queiroz Oliveira, Laio Ladislau Lopes Lima, David Freitas de Lucena, Clarissa Severino Gama, Danielle Macêdo & Silvânia Maria Mendes Vasconcelos. (2015) Alpha-lipoic acid alone and combined with clozapine reverses schizophrenia-like symptoms induced by ketamine in mice: Participation of antioxidant, nitrergic and neurotrophic mechanisms. Schizophrenia Research 165:2-3, pages 163-170.
Crossref
Crossref
D D Dickerson, K A Overeem, A R Wolff, J M Williams, W C Abraham & D K Bilkey. (2014) Association of aberrant neural synchrony and altered GAD67 expression following exposure to maternal immune activation, a risk factor for schizophrenia. Translational Psychiatry 4:7, pages e418-e418.
Crossref
Crossref
Anne Schmechtig, Jane Lees, Lois Grayson, Kevin J. Craig, Rukiya Dadhiwala, Gerard R. Dawson, J. F. William Deakin, Colin T. Dourish, Ivan Koychev, Katrina McMullen, Ellen M. Migo, Charlotte Perry, Lawrence Wilkinson, Robin Morris, Steve C. R. Williams & Ulrich Ettinger. (2013) Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy. Psychopharmacology 227:2, pages 331-345.
Crossref
Crossref
Vivek Bambole, Nilesh Shah, Shushma Sonavane, Megan Johnston & Amresh Shrivastava. (2013) Study of negatives symptoms in first episode schizophrenia. Open Journal of Psychiatry 03:03, pages 323-328.
Crossref
Crossref
Philip D. Harvey & Christopher R. Bowie. 2012. Handbook of Psychology, Second Edition. Handbook of Psychology, Second Edition.
I. Koychev, W. El‐Deredy, T. Mukherjee, C. Haenschel & J. F. W. Deakin. (2012) Core dysfunction in schizophrenia: electrophysiology trait biomarkers. Acta Psychiatrica Scandinavica 126:1, pages 59-71.
Crossref
Crossref
C.U. Correll, F. Cañas, I. Larmo, P. Levy, J.-M. Montes, A. Fagiolini, G. Papageorgiou, A. Rossi, R. Sturlason & M. Zink. (2020) Individualizing antipsychotic treatment selection in schizophrenia: characteristics of empirically derived patient subgroups. European Psychiatry 26:S1, pages 3-16.
Crossref
Crossref
Susan B. Powell, Martin Weber & Mark A. Geyer. 2012. Behavioral Neurogenetics. Behavioral Neurogenetics
251
318
.
Celso Arango & William T. Carpenter. 2010. Schizophrenia. Schizophrenia
09
23
.
Michael F. Egan & Tyrone D. Cannon. 2010. Schizophrenia. Schizophrenia
289
310
.
Rajiv Tandon, Henry A. Nasrallah & Matcheri S. Keshavan. (2010) Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future. Schizophrenia Research 122:1-3, pages 1-23.
Crossref
Crossref
Veena Kumari & Ulrich Ettinger. 2010. Latent Inhibition. Latent Inhibition
417
447
.
I. Wonodi & R. Schwarcz. (2010) Cortical Kynurenine Pathway Metabolism: A Novel Target for Cognitive Enhancement in Schizophrenia. Schizophrenia Bulletin 36:2, pages 211-218.
Crossref
Crossref
Peter Dome, Judit Lazary, Miklos Peter Kalapos & Zoltan Rihmer. (2010) Smoking, nicotine and neuropsychiatric disorders. Neuroscience & Biobehavioral Reviews 34:3, pages 295-342.
Crossref
Crossref
David L. Braff. 2010. Behavioral Neurobiology of Schizophrenia and Its Treatment. Behavioral Neurobiology of Schizophrenia and Its Treatment
349
371
.
Hans-Jürgen Möller. (2009) Development of DSM-V and ICD-11: Tendencies and potential of new classifications in psychiatry at the current state of knowledge. Psychiatry and Clinical Neurosciences 63:5, pages 595-612.
Crossref
Crossref
Bernard A Fischer & William T CarpenterJrJr. (2009) Will the Kraepelinian Dichotomy Survive DSM-V?. Neuropsychopharmacology 34:9, pages 2081-2087.
Crossref
Crossref
Paolo Olgiati, Laura Mandelli, Cristina Lorenzi, Elena Marino, Pirovano Adele, Barbara Ferrari, Diana De Ronchi & Alessandro Serretti. (2014) Schizophrenia: genetics, prevention and rehabilitation. Acta Neuropsychiatrica 21:3, pages 109-120.
Crossref
Crossref
Rajiv Tandon, Henry A. Nasrallah & Matcheri S. Keshavan. (2009) Schizophrenia, “just the facts” 4. Clinical features and conceptualization. Schizophrenia Research 110:1-3, pages 1-23.
Crossref
Crossref
Stephen I. Deutsch, Barbara L. Schwartz, Richard B. Rosse, John Mastropaolo, Ayman H. Fanous, Abraham Weizman, Jessica A. Burket & Brooke L. Gaskins. 2009. The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes. The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes
113
122
.
Brian Villumsen Broberg, Rebecca Dias, Birte Yding Glenthøj & Christina Kurre Olsen. (2008) Evaluation of a neurodevelopmental model of schizophrenia—Early postnatal PCP treatment in attentional set-shifting. Behavioural Brain Research 190:1, pages 160-163.
Crossref
Crossref
Hans-Jürgen Möller. (2008) Systematic of psychiatric disorders between categorical and dimensional approaches. European Archives of Psychiatry and Clinical Neuroscience 258:S2, pages 48-73.
Crossref
Crossref
Mark J. Millan & Mauricette Brocco. (2008) Cognitive Impairment in Schizophrenia: a Review of Developmental and Genetic Models, and Pro-cognitive Profile of the Optimised D3 > D2 Antagonist, S33138. Therapies 63:3, pages 187-229.
Crossref
Crossref
Declan N.C. Jones, Jane E. Gartlon, Arpi Minassian, William Perry & Mark A. Geyer. 2008. Animal and Translational Models for CNS Drug Discovery. Animal and Translational Models for CNS Drug Discovery
199
261
.
Mark J. Millan. 2008. Animal and Translational Models for CNS Drug Discovery. Animal and Translational Models for CNS Drug Discovery
1
57
.